Guidance

Live attenuated influenzaflu vaccine: patient group direction (PGD) template

PGD template to support the administration of live attenuated influenzaflu vaccine (Fluenz Trivalent®) in accordance with the national seasonal influenzaflu vaccination programme.programme

Applies to England

Documents

Influenza vaccine (Fluenz Trivalent®): patient group direction (PGD) template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Addendum to: live attenuated influenza vaccine nasal spray suspension (LAIV) patient group direction (PGD)

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This PGD template supports the administration of live attenuated influenza vaccine (LAIV) (Fluenz Trivalent®) as part of the national seasonal influenza vaccination programme.

LAIV PGD version 15.00 is valid from 1 September 2025 to 1 April 2026.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012).

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Productproduct Characteristicscharacteristics for the vaccine.

Updates to this page

Published 10 July 2024
Last updated 18 JulyAugust 2025 + show all updates
  1. Added 'Addendum to: Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD)'

  2. Added version 15, see page 4 for change history.

  3. First published.

Sign up for emails or print this page